CO6260094A2 - Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos - Google Patents
Anticuerpos novedosos anti-alpha5beta1 y usos de los mismosInfo
- Publication number
- CO6260094A2 CO6260094A2 CO10033130A CO10033130A CO6260094A2 CO 6260094 A2 CO6260094 A2 CO 6260094A2 CO 10033130 A CO10033130 A CO 10033130A CO 10033130 A CO10033130 A CO 10033130A CO 6260094 A2 CO6260094 A2 CO 6260094A2
- Authority
- CO
- Colombia
- Prior art keywords
- sequence
- amino acid
- acid sequence
- identifier
- sequence identifier
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 230000018103 negative regulation of vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97547107P | 2007-09-26 | 2007-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260094A2 true CO6260094A2 (es) | 2011-03-22 |
Family
ID=40329277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10033130A CO6260094A2 (es) | 2007-09-26 | 2010-03-19 | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7973138B2 (enExample) |
| EP (1) | EP2200700B1 (enExample) |
| JP (1) | JP2011501656A (enExample) |
| KR (1) | KR20100065162A (enExample) |
| CN (1) | CN101888878B (enExample) |
| AR (1) | AR066170A1 (enExample) |
| AU (1) | AU2008304452B2 (enExample) |
| BR (1) | BRPI0816049A2 (enExample) |
| CA (1) | CA2698609A1 (enExample) |
| CL (1) | CL2008002856A1 (enExample) |
| CO (1) | CO6260094A2 (enExample) |
| DK (1) | DK2200700T3 (enExample) |
| HR (1) | HRP20160308T1 (enExample) |
| HU (1) | HUE027911T2 (enExample) |
| MX (1) | MX2010003325A (enExample) |
| MY (1) | MY151191A (enExample) |
| NZ (1) | NZ584838A (enExample) |
| PE (1) | PE20091029A1 (enExample) |
| RU (1) | RU2490277C2 (enExample) |
| SI (1) | SI2200700T1 (enExample) |
| TW (1) | TWI547503B (enExample) |
| WO (1) | WO2009042746A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009042746A1 (en) | 2007-09-26 | 2009-04-02 | Genentech, Inc. | Novel antibodies |
| KR101523127B1 (ko) | 2009-03-25 | 2015-05-26 | 제넨테크, 인크. | 신규 항-α５β１ 항체 및 그의 용도 |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| WO2010129904A1 (en) | 2009-05-08 | 2010-11-11 | Genentech, Inc. | Humanized anti-egfl7 antibodies and methods using same |
| US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| KR102390445B1 (ko) * | 2012-12-26 | 2022-04-25 | 온코시너지, 인코포레이티드 | 항-인테그린 β1 항체 조성물 및 이의 이용 방법 |
| CA2898239A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
| PL2953972T3 (pl) * | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
| DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| JP7596298B2 (ja) * | 2019-04-01 | 2024-12-09 | クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114688461B (zh) * | 2020-12-31 | 2025-02-28 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
| CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
| CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
| EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
| US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| DE69531187T2 (de) * | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
| KR20010034327A (ko) | 1998-01-23 | 2001-04-25 | 플레믹 크리스티안 | 모노클로날 항체 항 αν-인테그린, 및 피브로넥틴에 대한ανβ6-인테그린 부착을 억제하기 위한 그의 용도 |
| EP1075277B2 (en) | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
| US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
| US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| JP2003517816A (ja) | 1999-08-11 | 2003-06-03 | イオス バイオテクノロジー， インコーポレイテッド | 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法 |
| US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| JP2004531249A (ja) | 2001-02-14 | 2004-10-14 | プロテイン デザイン ラブス インコーポレイティド | 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法 |
| AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| AU2002314901A1 (en) | 2001-06-04 | 2002-12-16 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| JP2005508144A (ja) | 2001-06-18 | 2005-03-31 | イオス バイオテクノロジー，インコーポレイティド | 卵巣癌の診断方法、卵巣癌のモジュレーターをスクリーニングする組成物及び方法 |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| EP1434881A4 (en) | 2001-09-17 | 2005-10-26 | Protein Design Labs Inc | METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS |
| US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20060241067A1 (en) | 2002-06-25 | 2006-10-26 | Varner Judith A | Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| AU2003299529A1 (en) | 2002-07-16 | 2004-06-03 | University Of Medicine And Dentistry Of New Jersey | Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| MXPA05005558A (es) * | 2002-11-26 | 2005-07-26 | Protein Design Labs Inc | Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis. |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004089988A2 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| BRPI0509177A (pt) * | 2004-03-24 | 2007-09-18 | Pdl Biopharma Inc | uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| WO2006062779A2 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
| EP1957476A1 (en) | 2005-11-23 | 2008-08-20 | AstraZeneca AB | L-alanine derivatives |
| WO2007060408A2 (en) | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
| WO2007091046A1 (en) | 2006-02-09 | 2007-08-16 | Astrazeneca Ab | Chemical compounds |
| MY159375A (en) * | 2006-03-21 | 2016-12-30 | Genentech Inc | Combinatorial therapy |
| CN101495515A (zh) | 2006-05-24 | 2009-07-29 | 拜耳先灵医药股份有限公司 | 免疫原性降低的高亲和力人及人源化抗α5β1整联蛋白功能阻断性抗体 |
| WO2009042746A1 (en) | 2007-09-26 | 2009-04-02 | Genentech, Inc. | Novel antibodies |
| EP2240203B1 (en) | 2008-02-05 | 2014-04-09 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
-
2008
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en not_active Ceased
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko not_active Abandoned
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 HR HRP20160308TT patent/HRP20160308T1/hr unknown
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101888878B (zh) | 2014-05-21 |
| TW200924794A (en) | 2009-06-16 |
| TWI547503B (zh) | 2016-09-01 |
| US8840887B2 (en) | 2014-09-23 |
| CA2698609A1 (en) | 2009-04-02 |
| US7973138B2 (en) | 2011-07-05 |
| CN101888878A (zh) | 2010-11-17 |
| AR066170A1 (es) | 2009-07-29 |
| WO2009042746A1 (en) | 2009-04-02 |
| US9284376B2 (en) | 2016-03-15 |
| HUE027911T2 (en) | 2016-11-28 |
| NZ584838A (en) | 2012-08-31 |
| EP2200700A1 (en) | 2010-06-30 |
| JP2011501656A (ja) | 2011-01-13 |
| RU2490277C2 (ru) | 2013-08-20 |
| EP2200700B1 (en) | 2016-01-13 |
| US20120148572A1 (en) | 2012-06-14 |
| CL2008002856A1 (es) | 2009-01-16 |
| AU2008304452B2 (en) | 2014-01-16 |
| AU2008304452A1 (en) | 2009-04-02 |
| DK2200700T3 (en) | 2016-04-11 |
| US20090098112A1 (en) | 2009-04-16 |
| MY151191A (en) | 2014-04-30 |
| HRP20160308T1 (hr) | 2016-04-22 |
| RU2010116184A (ru) | 2011-11-10 |
| US20120156129A1 (en) | 2012-06-21 |
| MX2010003325A (es) | 2010-04-09 |
| BRPI0816049A2 (pt) | 2019-09-24 |
| SI2200700T1 (sl) | 2016-04-29 |
| PE20091029A1 (es) | 2009-08-19 |
| KR20100065162A (ko) | 2010-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260094A2 (es) | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
| ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CR20150625A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
| ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| ECSP10010413A (es) | Inhibidores macrociclicos de serina proteasa | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| HN2008000949A (es) | Derivados de pirimidinil- aril- urea que son inhibidores de fgf | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| DOP2013000218A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
| AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
| EA201290504A1 (ru) | Новые производные (конденсированный гетероцикл-пиперидин)-(пиперазинил)-1-алканона или (конденсированный гетероцикл-пирролидин)-(пиперазинил)-1-алканона и их применение в качестве ингибиторов р75 | |
| CR11584A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
| ECSP088242A (es) | Combinaciones que comprenden dmxaa para el tratamiento de cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |